Bayer Bets On Oncology Pipeline, Vows To Increase 2017 R&D Budget
Bayer has launched an internal oncology R&D unit to speed up development of its pipeline cancer therapies and ensure the company is first to market with its late-stage treatment candidates, head of pharma Dieter Weinand told Scrip on the sidelines of the pharma's annual results conference.
You may also be interested in...
Bayer's head of pharma Dieter Weinand chats to Scrip on the sidelines of the company's 2017 annual results conference in Leverkusen, Germany, about putting more skin in the game this time around as the second wave of immuno-oncology innovation spills into the market.
Bayer's PI3 kinase inhibitor copanlisib now has accelerated approval in a common type of non-Hodgkin lymphoma, but the drug's competitive profile still awaits Phase III data.
Bayer's pharma head Dieter Weinand talks about his biggest issues with current value-based pricing assessments for new drugs and how companion diagnostics will pave the way to easier pricing of oncology therapies.